Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4725 | serology Wiki | 0.71 |
| drug1392 | Enhanced Usual Care Wiki | 0.71 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study aims to address treatment and service disparities and prevent disability among racial/ethnic and linguistic minority elders. It tests the effectiveness and implementation readiness of the Positive Minds-Strong Bodies Enhanced intervention (PMSB-E), a combined mental and physical health intervention designed to be implemented in low-resource community settings. This renewal grant project includes a streamlined intervention with new components designed to improve and maintain participant outcomes.
Description: >/= 70% of participants attending >/= 50% of their intervention sessions, reporting satisfaction with treatment.
Measure: Acceptability Time: 6 months at end of treatmentDescription: Widely used measure of depression and anxiety in clinical monitoring and outcome assessment.
Measure: Hopkins Symptom Checklist-25 (change) Time: Baseline and 3, 6, and 12 months after baselineDescription: Assessment of standing balance, timed 4-m walk, and timed test of five chair-rise repetitions, to assess functional limitations. A virtual option will be used while in person assessment is not possible due to COVID-19.
Measure: Short Physical Performance Battery (change) Time: Baseline and 3, 6, and 12 months after baselineDescription: Self-report instrument designed to measure both functional capacity and components of disability.
Measure: Late-Life Function and Disability Instrument (LLFDI) - functional component (change) Time: Baseline and 3, 6, and 12 months after baselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports